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Abstract 
A.2 Background 
A.2.1Substantial progresses in the management of peripheral arterial disease (PAD) 
have been made in the past two decades. Progress in the understanding of the 
endothelial-platelet interaction during health and disease state has resulted in better 
antiplatelet drugs that can prevent platelet aggregation, activation and thrombosis 
during angioplasty and stenting. A role in physiological and pathological angiogenesis 
in adults has been recently shown in bone marrow–derived circulating endothelial 
progenitors (BM-DCEPs) identified in the peripheral blood. These findings have paved 
the way for the development of therapeutic neovascularization techniques using 
endothelial progenitors. 
A.3 Methods 
A.3.1This pilot study includes five patients, aged 60 to 75, with a history of 
claudication and recruited from September 2010 to February 2011 at the A.O.U. 
Federico II of Naples. 
A.3.2PBMNCs have been implanted three times in the limb with the worst ABI value 
in all the patients included in the study. 
A.3.3The clinical follow up was performed during the subsequent 12 months from 
the beginning of the treatment. 
A.4 Results 
A.4.1In four patients there was a regression of ulcerative lesions. 
A.4.2One patient’s condition improved after the first implantation but later did not 
respond to the further treatments. 
A.4.3All patients achieved a pain relief as judged by the numeric pain scale. Pain 
relief remained satisfactory in three patients for one year. Pain gradually returned to 
the pre-treatment level in two patients. 
A.4.4All patients referred an ameliorating in their quality of life expressed even by 
an improvement in claudication free walking distance. 
A.4.5These improvements are reflected also by intra-arterial digital subtraction 
angiography (IADSA) that shows an improvement of arterial vascularization. 
A.5 Conclusions 
A.5.1The data from this study suggest an efficacy of BM-DCEPs implantation in 
terms of improvement of the vascularization and quality of life in patients affected by 
Peripheral Arterial Disease. Nevertheless a double-blind placebo-controlled study is 
needed to confirm our findings. 
Background 
B.1.1Peripheral arterial disease (PAD) is a pathologic condition associated with 
arteriosclerosis. The symptoms of PAD mainly affect the lower limbs resulting in 
intermittent claudication and rest pain. 
B.1.2Strategies to treat the limb ischemia and its resulting symptoms include both 
pharmacologic therapy and invasive procedures. Despite the available therapies, 25% 
of patients still progress each year to limb amputations. 
B.1.3Recently, bone marrow derived circulating endothelial progenitors (BM-DCEPs) 
have been identified in peripheral blood showing a role in physiological and 
pathological angiogenesis in the elderly. Preclinical studies showed BM-DCEPs to be 
useful when implanted in the ischemic limb for treatment of PAD. Based on the above 
mentioned observation, peripheral blood mononuclear cells implantation (PB-MNCs) 
has been used as therapeutic strategy for critical limb ischemia (CLI). 
B.1.4Although encouraging results have been obtained by using those therapies, the 
underlying mechanism is still not completely known. This is based on stimulation of 
angiogenesis by extracellular and cellular components. 
B.1.5This pilot study has been conducted to evaluate the efficacy of implanted 
PBMNCs on clinical outcomes in patients at a symptomatic stage of PAD. We also 
focused on molecular markers of neo-angiogenesis to elucidate the real mechanism 
underlying the creation and stabilization of neo-vessels and in which measure the 
circulating endothelial progenitors (CEPs) and muscle cells are involved. 
Methods 
B.2.1Five patients (three males) aged 60 to 75 (mean 65) with a history of 
claudication were recruited from September 2010 to February 2011 at the A.O.U. 
Federico II of Naples to participate in this pilot study, according to the Ethical 
Committee of Federico II University of Naples. Written informed consent was obtained 
before study participation. Patients who met the following inclusion/exclusion criteria 
were eligible for inclusion: those with symptomatic bilateral PAD (Fontaine scale ≥IIB 
- CFW distance ≤ 100 mt), aged 60 -75, where PAD has been diagnosed according to 
the clinical criteria and ABI < 0.6 (calculated as the worst value recorded at tibial 
anterior or posterior artery), with one or more stenosis of at least 50% in an artery of 
the lower limbs shown by duplex, angio-RM or intra-arterial digital subtraction 
angiography (IADSA) not eligible for endovascular revascularization treatments and 
with at least 2 comorbidities (e.g., hypertension, hyperlipaemia, obesity and/or 
carotid, coronary obstructions). 
B.2.2Exclusion criteria were: a) estimated survival less than 6 months; b) acute 
stage of severe limb ischemia with severe inflammatory process affecting the patient’s 
life that required limb amputation to avert grave outcome; c) lymphopenia and/or 
thrombocytopenia and/or hemophilia; d) diabetes; e) chronic inflammatory diseases; 
f) connective tissues diseases; g) acute infectious processes; h) fever, physical 
trauma or surgery in the previous 45 days; i) acute illness, such as acute coronary or 
limb ischemia within 16 weeks; j) cancer. A detailed medical history was compiled for 
all patients with special attention given to cardio-vascular risk factors. The presence of 
arterial hypertension was defined with a blood pressure ≥ 140/90 mmHg in at least 
two measurements or current treatment with anti-hypertensive drugs. The presence 
of dyslipidemia was defined as total cholesterol >200 mg/dl, LDL-cholesterol >100 
mg/dl, triglycerides >150 mg/dl, or current treatment with lipid-lowering drugs. The 
presence of diabetes was defined by concentrations of fasting plasma glucose ≥ 126 
mg/dl or current treatment with oral antidiabetics and/or insulin. 
B.2.3All of the patients included in the study were treated three times with PBMNCs 
(one injection every two months for a 6 month treatment) implantation in the limb 
with the worst ABI value. Tissue samples from the gastrocnemius of the interested leg 
were collected before the first cells implantation (T1) and before the third cycle of 
cells implantation to detect the markers of neoangiogenesis reported in Fig. 1. Blood 
samples were collected at the following times: T0 – enrollment; T1 before the 
implantation; 1 and 2 weeks and then 1 month after the first implantation; T2 before 
the second implantation; 1 and 2 weeks and then 1 month after the second 
implantation; T3 before the third implantation; 1 and 2 weeks and then 1 month after 
the third implantation. 
 
Fig. 1. Follow up scheme to evaluate the patient’s response to the treatment. 
B.2.4The clinical follow up was performed during the subsequent 12 months from 
the beginning of the treatment at the followings time points: T0 – enrolment; 1 and 2 
weeks and then 1 month after the first implantation; 1 and 2 weeks and then 1 month 
after the second implantation; 1 and 2 weeks and then 1 month after the third 
implantation; after 12 months from the time of enrolment. The following parameters 
were considered: 1) clinical history reporting a) onset of complication during the 
follow up, b) require of specific surgical treatment for PAD, c) return or progression of 
symptoms of claudication, d) evaluation of trophic lesions [1] documented also by 
photography, e) evaluation of the pain (using the pain numeric scale 0-10); f) a multi-
parametric questionnaire on the quality of life analysing the previous 4 weeks named 
SF-36 [2]; 2) improvement in walking (Fontaine scale) measured as claudication-free 
walking distance (CFWD) and maximal walking distance (MWD), using the Skinner-
Gardner protocol and the 6-minute walk distance test; 3) measurement of the ABI 
(ankle-brachial pressure index or Windsor index); 4) pheripheral arterial diameter and 
blood flow characteristics (peak, volume, pulse systolic rates of blood flow, indices of 
vessels stiffness) by Duplex Ultrasonography; 5) evolution of the stenosis and 
neoangiogenesis documented by intra-arterial digital subtraction angiography (IADSA) 
(Fig.1). 
Results 
B.3.1During the one year follow-up no complications or need of surgical treatments 
were registered. In four patients there was a regression of ulcerative lesions after the 
second treatment with a complete resolution of the lesions one month after the third 
treatment. A 73 year old male patient condition improved after the first implantation 
but then did not respond to further treatments. In this patient necrosis was seen in 
two sites; on the tips of the left big toe and middle fingers and in three sites on the 
right leg. The necrotic tissue on the top of the left big toe fell off spontaneously and 
the ulcer undermined deeper in the necrotic area epithelialized and healed eventually 
after one year. Unfortunately, he died 14 months after the enrolment due to a 
cardiovascular complication. Relief of pain as judged by the numeric pain scale was 
achieved in all patients in a week and continued up to one month in four patients. 
Pain relief remained satisfactory in three patients for one year. However pain 
gradually returned to the pre-treatment level in two patients. 
B.3.2All patients referred an ameliorating in their quality of life expressed even by 
an improvement in claudication free walking distance more evident in three of five 
patients. 
B.3.3The ABI surprisingly did not reach the expected improvement, remaining in a 
mean of 0.6 (mean baseline values 0.4), and not showing a direct relation between 
the clinical features and the instrumental detections. Therefore, We should be careful 
when using ABI as follow up and as a diagnostic parameter to monitor neo-
angiogenesis. However the number of patients is too small to assume that our results 
are definitive. 
B.3.4IADSA in three patients showed an apparent increase of visible arteries after 
treatment (Figure 2). Such a long-term effect could be obtained to bona fide 
angiogenesis induced by repeated implantation of PB-MNCs. 
 
Fig. 2. Left, at enrolment, Right, after treatment. 
Discussion and conclusions 
B.4.1Peripheral vascular disease (PVD) is known to affect 10% to 15% of the adult 
population in developed countries and is often associated with coronary artery disease. 
Arteriosclerosis obliterans (ASO) is the most common cause of PVD affecting the lower 
limbs. The two cardinal symptoms of limb ischemia are intermittent claudication and 
rest pain. Intermittent claudication (IC), defined as a symptomatic deficiency in blood 
supply to the exercising muscle that is relieved with rest, is generally a reliable 
indicator of occlusive arterial disease. This disorder results from an imbalance 
between supply and demand of blood flow that fails to satisfy ongoing metabolic 
requirements. Rest pain occurs in patients with critical limb ischemia and often 
coincides with ischemic ulceration and/or gangrene. Treatment of PVD includes 
pharmacotherapy, percutaneous transluminal angioplasty, and vascular surgery. The 
treatment chose depends on the severity of symptoms and the arteries involved. 
However, 30% to 50% of patients with critical limb ischemia require limb amputation 
within one year because of a poor response to treatment [3]. Recent progress in 
understanding the mechanisms underlying vascular formation in adults as well as 
during embryogenesis has opened up a therapeutic avenue for patients without any 
current options [4]. Initial therapeutic approaches were aimed at delivering 
angiogenic factors, such as vascular endothelial growth factors (VEGF) and fibroblast 
growth factor-2, to ischemic tissues by using recombinant proteins or vectors 
encoding these factors [5,6]. A number of preclinical studies reported improvement of 
perfusion by such methods in animal models with limb ischemia [7,8]. Although the 
initial nonrandomized clinical trials showed beneficial effects, the results of controlled 
clinical trials were not consistent. More recently, bone marrow–derived circulating 
endothelial progenitors (BM-DCEPs) were identified in the peripheral blood [9,10] and 
have been shown to contribute to both physiological and pathological angiogenesis in 
adults [11,12]. These findings have led to the development of therapeutic 
neovascularization techniques using endothelial progenitors. Preclinical studies 
indicated that implantation of bone marrow mononuclear cells (BM-MNC), which 
contain endothelial progenitors, into ischemic limbs was very effective [13-15]. The 
results of the first clinical trial showed that implantation of BM-MNC significantly 
improved the tissue oxygen concentration and blood flow in ischemic limbs, resulting 
in a decrease of rest pain and the involution of ischemic ulcers [16]. Although 
promising results have been obtained, the mechanism by which cell therapy improves 
limb ischemia is largely unknown. Because direct incorporation of implanted cells into 
newly formed vessels is reported to be relatively rare, it has been assumed that 
angiogenic factors secreted by implanted cells are responsible for the efficacy of cell 
therapy [17,18]. Implantation of mononuclear cells increased the production of the 
angiogenic cytokines in muscle cells. A deficiency of the angiogenic cytokines in 
muscle cells blunted the ability of implanted cells to increase vascularization, 
suggesting that muscle cells and not mononuclear cells were important as a source of 
the angiogenic cytokines. Subsequently, Tateno et al. discovered that angiogenic 
cytokines, especially IL-1beta, were associated with the response to treatment. Many 
previous studies by other groups suggested that angiogenic factors secreted by 
implanted cells play a critical role in therapeutic neovascularization [17,18]. In 
contrast, Tateno's group in vitro and in vivo studies demonstrated that the implanted 
mononuclear cells did not secrete sufficient cytokines for neovascularization but, 
instead, stimulated muscle cells to produce IL-1beta. This is consistent with the 
observation that most of the implanted cells disappeared from the ischemic tissues as 
early as 3 days after implantation, which is before the reconstruction of the vascular 
system started. Thus, it is likely that muscle cells but not implanted cells are a major 
source of angiogenic cytokines in ischemic limbs [19]. Recently, a Japanese study 
analyzed the long-term outcome of therapeutic neovascularization with PB-MNCs. 
Overall, improvement of ischemic symptoms was observed in 60% to 70% of the 
treated patients. The annual major amputation rate decreased to 10%, and the 
mortality rate was reduced to 20% at 2 years and 30% at 3 years in their patients. 
Their results, together with previous reports suggest that the performance of 
therapeutic neovascularization with PB-MNCs might be safe and effective for patients 
with critical limb ischemia. Although this study was not placebo-controlled and 
therefore cannot assess the efficacy and safety of cell therapy only with their results, 
they conclude that therapeutic angiogenesis with PB-MNCs is a safe and potentially 
effective treatment for critical limb ischemia [20]. 
B.4.2Although the results of this pilot study suggest an efficacy of BM-DCEPs 
implantation in terms of improvement of the vascularization and quality of life in 
patients affected by peripheral arterial disease, double-blind placebo-controlled 
studies are needed to confirm our findings. 
B.4.3Such a study is currently in progress. 
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